Canterbury DHB
Smouldering Myeloma should not be treated. Overall, only 10% of SMM patients progress to symptomatic myeloma each year for the first 5 years. The risk decreases to 3% per year for the next 5 years and 1% per year thereafter. Risk of progression can be further estimated as follows:
|
Definition |
Number who progress at 5 years |
Median time to progression |
Low |
>30 g/L and <10% BM PC |
15% |
19 years |
Medium |
<30 g/L but >10% BM PC |
43% |
8years |
High |
>30 g/L and >10% BM PC |
69% |
2 years |
Topic Code: 5578